Listed

PharmaCyte Biotech, Inc.: Form 10-K for the period ended Apr 30, 2021

Filed with the SEC on Aug 10, 2021 and accepted by EDGAR at Aug 10, 2021, 06:03 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2021-04-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue12 months2020-05-01 to 2021-04-30$0us-gaap:Revenues
Research and development12 months2020-05-01 to 2021-04-30$916.2kus-gaap:ResearchAndDevelopmentExpense
Operating income12 months2020-05-01 to 2021-04-30−$3.6mus-gaap:OperatingIncomeLoss
Interest expense12 months2020-05-01 to 2021-04-30$3.0kus-gaap:InterestExpense
Income tax12 months2020-05-01 to 2021-04-30$0us-gaap:IncomeTaxExpenseBenefit
Net income12 months2020-05-01 to 2021-04-30−$3.6mus-gaap:NetIncomeLoss
Diluted shares (weighted)12 months2020-05-01 to 2021-04-301,448,285 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow12 months2020-05-01 to 2021-04-30−$3.3mus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2021-04-30$2.2mus-gaap:Cash
Current assetsAt period end2021-04-30$2.3mus-gaap:AssetsCurrent
Total assetsAt period end2021-04-30$7.4mus-gaap:Assets
Current liabilitiesAt period end2021-04-30$724.8kus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2021-04-30$724.8kus-gaap:Liabilities
Shareholders' equityAt period end2021-04-30$6.7mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001683168-21-003377. Last ingested by Listed: Nov 14, 2026, 20:52 ET. Listed shows no prices and gives no investment advice.